Vera Therapeutics, Inc. (VERA )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol VERA
- Company Vera Therapeutics, Inc.
- Price $27.66
- Changes Percentage -1.85
- Change -0.52
- Day Low $27.17
- Day High $28.5
- Year High $51.61
- Year Low $25.99
- Market Cap $1,763,277,978
- Price Avg 50 EMA (D) $33.79
- Price Avg 200 EMA (D) $38.79
- Exchange NASDAQ
- Volume 392,992
- Average Volume 835,115
- Open $28.32
- Previous Close $28.18
- EPS -2.75
- PE -10.06
- Earnings Announcement 2025-05-07 12:30:00
- Shares Outstanding $63,748,300
Company brief: VERA THERAPEUTICS, INC. (VERA )
- Healthcare
- Biotechnology
- Dr. Marshall W. Fordyce M.D.
- https://veratx.com
- US
- N/A
- 05-14-2021
- US92337R1014
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.